Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
1. JNJ will report Q3 earnings on October 14. 2. Analysts expect earnings of $2.76 per share, up from $2.42. 3. FDA approved Simponi for children with active ulcerative colitis. 4. Analysts have raised price targets for JNJ significantly. 5. Shares rose 0.7% recently, closing at $191.08.